Protect Yourself While There’s Still Time …

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.

Marcio Souza Biography and Net Worth

CEO of Praxis Precision Medicines

Marcio Souza has served as a director and our President and Chief Executive Officer since April 2020. Prior to joining us, Mr. Souza was at PTC Therapeutics, Inc., or PTC, where he served as its Chief Operating Officer from May 2017 to April 2020 and its Senior Vice President and Head of Product Strategy from July 2016 to May 2017. Prior to joining PTC, Mr. Souza served in positions of increasing responsibility at NPS Pharmaceuticals, Inc., Shire Human Genetic Therapies Inc. and Sanofi Genzyme Corporation. From May 2019 to May 2020, Mr. Souza also served on the board of directors of Clearpoint Neuro, Inc. (previously MRI Interventions, Inc.). Mr. Souza received a degree in pharmacy and biochemistry with a specialization in toxicology and clinical analysis from the University of São Paulo and an M.B.A. from Fundação Dom Cabral.

What is Marcio Souza's net worth?: The estimated net worth of Marcio Souza is at least $164,400.00 as of June 27th, 2023. Mr. Souza owns 3,000 shares of Praxis Precision Medicines stock worth more than $164,400 as of April 26th. This net worth approximation does not reflect any other assets that Mr. Souza may own. Additionally, Mr. Souza receives a salary of $1,180,000.00 as CEO at Praxis Precision Medicines. Learn More about Marcio Souza's net worth.
How old is Marcio Souza?: Mr. Souza is currently 44 years old. There are 3 older executives and no younger executives at Praxis Precision Medicines. Learn More on Marcio Souza's age.
What is Marcio Souza's salary?: As the CEO of Praxis Precision Medicines, Inc., Mr. Souza earns $1,180,000.00 per year. Learn More on Marcio Souza's salary.
How do I contact Marcio Souza?: The corporate mailing address for Mr. Souza and other Praxis Precision Medicines executives is 101 MAIN STREET #1210, CAMBRIDGE MA, 02142. Praxis Precision Medicines can also be reached via phone at 617-300-8460 and via email at [email protected]. Learn More on Marcio Souza's contact information.
Has Marcio Souza been buying or selling shares of Praxis Precision Medicines?: Marcio Souza has not been actively trading shares of Praxis Precision Medicines during the last ninety days. Most recently, on Tuesday, June 27th, Marcio Souza bought 666 shares of Praxis Precision Medicines stock. The stock was acquired at an average cost of $15.90 per share, with a total value of $10,589.40. Following the completion of the transaction, the chief executive officer now directly owns 3,000 shares of the company's stock, valued at $47,700. Learn More on Marcio Souza's trading history.
Are insiders buying or selling shares of Praxis Precision Medicines?: In the last twelve months, Praxis Precision Medicines insiders bought shares 2 times. They purchased a total of 1,632 shares worth more than $35,946.90. The most recent insider tranaction occured on October, 5th when Director Jill Desimone bought 966 shares worth more than $25,357.50. Insiders at Praxis Precision Medicines own 2.7% of the company. Learn More about insider trades at Praxis Precision Medicines.
Information on this page was last updated on 10/5/2023.

Marcio Souza Insider Trading History at Praxis Precision Medicines

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/27/2023	Buy	666	$15.90	$10,589.40	3,000
3/23/2023	Buy	2,333	$12.90	$30,095.70	15,086
6/8/2022	Buy	1,800	$27.75	$49,950.00	12,612
8/18/2021	Buy	636	$236.85	$150,636.60
11/10/2020	Buy	256	$391.20	$100,147.20	1,630

Marcio Souza Buying and Selling Activity at Praxis Precision Medicines

Praxis Precision Medicines Company Overview

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Today's Range

Now: $54.80

$51.80

$56.42

50 Day Range

MA: $51.72

$40.20

$62.18

2 Week Range

Now: $54.80

$12.45

$67.21

Volume

140,175 shs

Average Volume

220,081 shs

Market Capitalization

$725.55 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.89

Protect Yourself While There’s Still Time …

From Weiss Ratings | Ad